Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Share price taken down
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon May 16, 2021 2:18pm
270 Views
Post# 33211553

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Share price taken down

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Share price taken down
HarveyTwoface wrote: I appreciate your very intelligent answer. Thanks for being a beacon in the board darkness.


Thanks Harvey ... just trying to understand our potential and the potential of the drug.

What did Dan say ... 20+ molecules and we are presently using 3 of them ... something like that.
I think one is for the NSAIDs - one for the the IBD drug - and one was potentially for the future replacement to our NSAIDs (likely for 340 trials at this time).  Lots of others and maybe we're adding with the academic studies.  There are potentially tuneables out there and we need to get to them first in this wild-west of drug development in gaseous mediators.

Something else I see w.r.t. H2S donors is the types of release mechanisms that exist.
First there's hydrolysis-triggering molecules but they have less control than others (assuming).
There are pH-controlled H2S release agents, Thiol-triggered, Enzime-triggered ... and the list goes on.

I just can't see what ATE actually has dibs on.  Hoping that becomes more and more apparent with time - or with other digging that people do.

Cheers all - may the rest of 2021 be more fun than the first part of the year.    : )
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities